We are live on ! Find out more
AGP

Artia Global Partners Portfolio holdings

AUM $499M
1-Year Est. Return 186.05%
This Fund
S&P 500
This Quarter Est. Return
+13.6%
1 Year Est. Return
+186.05%
3 Year Est. Return
+672.09%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$344M
AUM Growth
+$103M
Cap. Flow
+$45.6M
Cap. Flow %
13.27%
Top 10 Hldgs %
87.9%
Holding
39
New
12
Increased
2
Reduced
3
Closed
8

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$38.8M
2
NVO
Novo Nordisk
NVO
+$3.93M
3
INSM icon
Insmed
INSM
+$1.94M
4
VRNA
Verona Pharma
VRNA
+$1.93M
5
OCUL icon
Ocular Therapeutix
OCUL
+$1.3M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$10.9M
2
ROIV icon
Roivant Sciences
ROIV
+$10.7M
3
ETNB
89bio
ETNB
+$7.19M
4
ARGX icon
argenx
ARGX
+$6.99M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$6.93M

Sector Composition

Rank Sector Weight
1 Healthcare 73.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVO
1
Novo Nordisk
NVO
$216B
$74.6M 21.72%
721,507
+39,695
+6% +$3.93M
LLY icon
2
Eli Lilly
LLY
$1.07T
$54M 15.7%
92,593
+66,400
+254% +$38.8M
MRK icon
3
Merck
MRK
$324B
$35.9M 10.44%
329,200
– –
CYTK icon
4
CALL
Cytokinetics
CYTK
$11B
$33.8M 9.83%
+404,900
New +$14.7M
CYTK icon
5
PUT
Cytokinetics
CYTK
$11B
$33.4M 9.73%
+400,500
New +$14.5M
LLY icon
6
PUT
Eli Lilly
LLY
$1.07T
$23.3M 6.78%
+40,000
New +$23.3M
ABBV icon
7
AbbVie
ABBV
$458B
$14.1M 4.09%
90,821
– –
ARGX icon
8
argenx
ARGX
$57.4B
$13M 3.79%
34,238
-15,000
-30% -$6.99M
AZN icon
9
AstraZeneca
AZN
$263B
$12.8M 3.74%
95,376
– –
VKTX icon
10
Viking Therapeutics
VKTX
$4.04B
$7.14M 2.08%
383,580
– –
AXSM icon
11
Axsome Therapeutics
AXSM
$12.4B
$6.99M 2.03%
87,848
– –
NBIX icon
12
Neurocrine Biosciences
NBIX
$17.7B
$5.93M 1.73%
45,000
– –
ITCI
13
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$2.98M 0.87%
41,600
– –
BMRN icon
14
BioMarin Pharmaceuticals
BMRN
$11.5B
$2.79M 0.81%
28,885
-49,580
-63% -$4.39M
CYTK icon
15
Cytokinetics
CYTK
$11B
$2.68M 0.78%
+32,113
New +$1.16M
VRNA
16
DELISTED
Verona Pharma
VRNA
$2.6M 0.76%
+130,790
New +$1.93M
PTGX icon
17
Protagonist Therapeutics
PTGX
$8.75B
$2.58M 0.75%
112,340
– –
PCVX icon
18
Vaxcyte
PCVX
$7.89B
$2.42M 0.7%
38,555
– –
INSM icon
19
Insmed
INSM
$23.2B
$2.32M 0.68%
+74,936
New +$1.94M
OCUL icon
20
Ocular Therapeutix
OCUL
$1.86B
$1.96M 0.57%
+440,000
New +$1.3M
PLRX icon
21
Pliant Therapeutics
PLRX
$67.5M
$1.81M 0.53%
100,000
– –
CRL icon
22
Charles River Laboratories
CRL
$10.9B
$1.63M 0.47%
6,905
– –
EYPT icon
23
EyePoint Inc
EYPT
$1.02B
$1.16M 0.34%
+50,000
New +$559K
WAT icon
24
Waters Corp
WAT
$36.8B
$937K 0.27%
2,845
– –
IMVT icon
25
Immunovant
IMVT
$8.09B
$901K 0.26%
+21,397
New +$787K
1
2

Similar funds

MIP
Marietta Investment Partners Milwaukee, Wisconsin $499M AUM 41.06% 1-Year Est. Return
H2CM
H/2 Credit Manager Stamford, Connecticut $500M AUM 24.68% 1-Year Est. Return
HCI
Harraden Circle Investments New York $499M AUM 24.03% 1-Year Est. Return
KCL
KR Capital LP New York City, New York $499M AUM
PPC
Park Place Capital Homewood, Alabama $499M AUM 14.38% 1-Year Est. Return
HIC
Holderness Investments Company Greensboro, North Carolina $498M AUM 34.39% 1-Year Est. Return
CWM
Centric Wealth Management Chicago, Illinois $501M AUM 15.27% 1-Year Est. Return
HSG
Helen Stephens Group Fort Worth, Texas $501M AUM 16.23% 1-Year Est. Return

Artia Global Partners's Q4 2023 Portfolio in Review

As of Q4 2023, Artia Global Partners held 39 positions worth $344M, up 43% from $241M the previous quarter. Its ten largest holdings account for 88% of the portfolio.

Artia Global Partners deployed $45.6M of net new capital in Q4 2023, opening 12 new positions and adding to 2 existing holdings. Its largest new stake was Insmed: 74,936 shares worth $2.32M.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was argenx, an estimated $6.99M trimmed.

  • Artia Global Partners's largest Q4 2023 buy was Insmed: 74,936 shares worth $2.32M.
  • Artia Global Partners added most to Eli Lilly in Q4 2023, an estimated $38.8M increase.
  • Artia Global Partners's biggest Q4 2023 reduction was argenx, cutting an estimated $6.99M.
  • Artia Global Partners fully exited Seagen Inc. Common Stock in Q4 2023, selling an estimated $10.9M.
  • Artia Global Partners's ten largest holdings make up 88% of its $344M portfolio in Q4 2023.
  • Artia Global Partners opened 12 new positions and closed 8 in Q4 2023.
  • Artia Global Partners's portfolio value rose 43% quarter-over-quarter to $344M.

Based on Artia Global Partners's 13F filing for Q4 2023, filed 14 Feb 2024.